Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections.
Posaconazole is used for prophylaxis for invasive fungal infections (IFIs) among patients with hematologic malignancies. We compared the incidence of breakthrough IFIs and early discontinuation between patients receiving delayed-release tablet and oral suspension formulations of posaconazole. This was a retrospective cohort study of patients receiving posaconazole between 1 January 2010 and 30 June 2016. We defined probable or proven breakthrough IFIs using the European Organization for Research and Treatment of Cancer (EORTC) criteria. Overall, 547 patients received 860 courses of posaconazole (53% received the oral suspension and 48% received the tablet); primary indications for prophylaxis were acute myeloid leukemia (69%), graft-versus-host disease (18%), and myelodysplastic syndrome (3%). There were no significant differences in demographics or indications between patients receiving the different formulations. The incidence and incidence rate of probable or proven IFIs were 1.6% and 3.2 per 10,000 posaconazole days, respectively. There was no significant difference in the rate of IFIs between suspension courses (2.8 per 10,000 posaconazole days) and tablet courses (3.7 per 10,000 posaconazole days) (rate ratio = 0.8, 95% confidence interval [CI] = 0.3 to 2.3). Of the 14 proven or probable cases of IFI, 8/14 had posaconazole serum concentrations measured, and the concentrations in 7/8 were above 0.7 μg/ml. Posaconazole was discontinued early in 15.5% of courses; however, the frequency of discontinuation was also not significantly different between the tablet (16.5%) and oral suspension (14.6%) formulations (95% CI for difference = -0.13 to 0.06). In conclusion, the incidence of breakthrough IFIs was low among patients receiving posaconazole prophylaxis and not significantly different between patients receiving the tablet formulation and those receiving the oral suspension formulation.
['Furuno|Jon P|JP|', 'Tallman|Gregory B|GB|0000-0002-2965-1355', 'Noble|Brie N|BN|', 'Bubalo|Joseph S|JS|', 'Forrest|Graeme N|GN|', 'Lewis|James S|JS|', 'Bienvenida|Ana F|AF|', 'Holmes|Courtney A|CA|', 'Weber|Bo R|BR|', 'McGregor|Jessina C|JC|0000-0002-6093-5444']
D000284:Administration, Oral D000368:Aged D000935:Antifungal Agents D005260:Female D006801:Humans D000072742:Invasive Fungal Infections D008297:Male D008875:Middle Aged D012189:Retrospective Studies D013535:Suspensions D014230:Triazoles
formulation posaconazole prophylaxis invasive fungal infection antifungal agents medical outcomes